

DIHYDRODIPYRAZOLOPYRIDINONE INHIBITORS OF B7-1

BACKGROUND OF THE INVENTION

5 This application claims priority from copending provisional application Serial Number 60/399,161, filed July 29, 2002, the entire disclosure of which is hereby incorporated by reference.

 Regulation of T cell responses plays a primary role in determining the outcome of auto-immune disease, the development of tumor immunity, and graft
10 survival following transplantation (Bluestone, et.al. *Annu. Rev. Immunol.* 1996, *14*, 233-258.; Kuchroo, et. al. *Crit. Rev. Immunol.* 1998, *18*, 389-418.; Guinan, et. al. *N. Engl. J. Med.* 1999, *340*, 1704-1714.; Abrams et. al. *J. Exp. Med.* 2000, *192*, 681-694). These immune responses are controlled by the interaction of molecules on T cell and antigen presenting cell surfaces. Activation of T cells requires two signals,
15 an antigen-specific signal delivered through T cell antigen receptor, and a second co-stimulatory signal. This co-stimulatory signal dictates the outcome for T cells through the binding of B7-1 and B7-2 expressed on antigen presenting cells to CD28 and CTLA-4 on T cells. CD28 engagement by B7-1 or B7-2 amplifies T cell receptor signaling and stimulates production of cytokines required for T-cell proliferation. On
20 the other hand, CTLA-4 engagement by B7-1 or B7-2 down regulates the immune response (Allison, et. al. *Nature* 1992, *356*, 607-609.; Bluestone, et. al. *Immunity* 1994, *1*, 405-413.; Thompson, et. al. *Science* 1995, *270*, 985-988). In experimental disease models, altering these co-stimulatory signals has profound effects on immunity. Blocking B7/CD28 interactions with monoclonal antibodies or soluble
25 receptors results in immunosuppression and enhanced allograft survival, while B7/CTLA-4 blockade results in enhanced anti-tumor immune responses (Larsen, et. al. *Nature* 1996, *381*, 434-438). Consequently, agents, such as small molecules, which act as inhibitors of cell-cell interactions may be useful in the development of effective immunomodulatory medicines.

Therefore, it is an object of this invention to provide compounds which are useful as immunotherapeutic agents in the treatment of transplant rejection, autoimmune disease or graft vs host disease.


It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment of transplant rejection, autoimmune disease or graft vs host disease.

It is a feature of this invention that the compounds provided may be used to further study and elucidate the interactions of B7-1 with the CD28 receptor.

These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.

SUMMARY OF THE INVENTION

The present invention provides a compound of formula I



(I)

wherein

R_1 and R_4 are each independently H, C_1 - C_{10} alkyl optionally substituted with one or more halogen, hydroxy, C_1 - C_4 alkoxy, CO_2R_6 , $CONR_7R_8$, C_3 - C_7 cycloalkyl or optionally substituted phenyl groups, or phenyl optionally substituted with one to three halogen, hydroxy, C_1 - C_6 haloalkyl, C_1 - C_4 alkoxy, CO_2R_9 , $NR_{10}R_{11}$ or CN groups;

R_2 is H, C_1 - C_6 alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C_1 - C_6 alkyl,

C₁-C₆haloalkyl, C₁-C₄alkoxy, hydroxy, CHO, NO₂, CN, CO₂R₁₂ or
 NR₁₃R₁₄ groups,
 phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy,
 C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl,
 5 benzyloxy, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 naphthyl optionally substituted with one to three halogen, NO₂, CN,
 hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy,
 benzyl, benzyloxy, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 C₅-C₇cycloheteroalkyl optionally substituted with one to three halogen,
 10 NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or
 NR₁₈R₁₉ groups, or
 heteroaryl optionally substituted with one to three halogen, NO₂, CN, C₁-
 C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups;
 R₃ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy,
 15 C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl,
 phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or
 NR₂₄R₂₅ groups,
 cycloheteroalkyl optionally substituted with one or more halogen, NO₂,
 CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy,
 20 phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃
 or NR₂₄R₂₅ groups, or
 heteroaryl optionally substituted with one or more halogen, NO₂, CN,
 hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy,
 phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃
 25 or NR₂₄R₂₅ groups;
 R₆, R₉, R₁₂, R₁₇, R₂₀ and R₂₆ are each independently H or a C₁-C₆alkyl, C₃-C₇
 cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl or heteroaryl
 group each optionally substituted;
 n is 0 or an integer of 1 or 2; and
 30 R₇, R₈, R₁₀, R₁₁, R₁₃, R₁₄, R₁₈, R₁₉, R₂₁, R₂₂, R₂₄ and R₂₅ are each
 independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl,
 C₅-C₇cycloheteroalkyl or heteroaryl group each optionally substituted or
 each of R₇ and R₈ or R₁₀ and R₁₁ or R₁₃ and R₁₄ or R₁₈ and R₁₉ or R₂₁ and

R_{22} or R_{24} and R_{25} may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or


the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

- 5 The present invention also provides methods and compositions useful for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs host disease.

DETAILED DESCRIPTION OF THE INVENTION

- 10 Full T cell activation requires both an antigen-specific and a second co-stimulatory signal. Co-stimulation dictates the outcome for T cells through the binding of B7-1 and B7-2 expressed on antigen-presenting cells to CD28 and CTLA4 on T cells (Greenfield, E.A., Nguyen, K.A. and Kuchroo, V.K. (1998) Critical Review of Immunology, 18, 389-418 and Lenschow, D.J., Walunas, T.L. and Bluestone, J.A. 15 (1996) Annual Review of Immunology, 14, 233-258). Animal studies and clinical trials with protein antagonists of these interactions indicate considerable promise for immunotherapy in transplantation and autoimmune disease.

- Surprisingly, it has now been found that dihydrodipyrzolo-pyridinone compounds of formula I are effective inhibitors of B7-1/CD28 binding. Equilibrium 20 dialysis demonstrates that compounds of formula I bind specifically to human B7-1 at a common site. Occupancy of this site by said inhibitors blocked B7-1 binding not only to CD28, but also to CTLA-4 (although at much higher concentrations of inhibitor). Accordingly, the present invention provides dihydrodipyrzolo-pyridinone B7-1 inhibitors of formula I



(I)

wherein

- R_1 and R_4 are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₆, CONR₇R₈, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or
- 5 phenyl optionally substituted with one to three halogen, hydroxy, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₉, NR₁₀R₁₁ or CN groups;
- R_2 is H, C₁-C₆alkyl optionally substituted with a phenyl, naphthyl or heteroaryl group each group optionally substituted with one to three C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, hydroxy, CHO, NO₂, CN, CO₂R₁₂ or
- 10 NR₁₃R₁₄ groups,
- phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
- naphthyl optionally substituted with one to three halogen, NO₂, CN,
- 15 hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
- C₅-C₇cycloheteroalkyl optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups, or
- 20 heteroaryl optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups;
- R_3 is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or
- 25 NR₂₄R₂₅ groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or
- 30 heteroaryl optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups;

R_6 , R_9 , R_{12} , R_{17} , R_{20} and R_{26} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted;


n is 0 or an integer of 1 or 2; and

- 5 R_7 , R_8 , R_{10} , R_{11} , R_{13} , R_{14} , R_{18} , R_{19} , R_{21} , R_{22} , R_{24} and R_{25} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl or heteroaryl group each optionally substituted or each of R_7 and R_8 or R_{10} and R_{11} or R_{13} and R_{14} or R_{18} and R_{19} or R_{21} and R_{22} or R_{24} and R_{25} may be taken together with the nitrogen atom to which
- 10 they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

- As used in the specification and claims, the term halogen designates F, Cl, Br or I and the term cycloheteroalkyl designates a C_5 - C_7 cycloalkyl ring system
- 15 containing 1 or 2 heteroatoms, which may be the same or different, selected from N, O or S and optionally containing one double bond. Exemplary of the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein X is NR, O or S; and R is H or an optional substituent as described hereinbelow:

20



- Similarly, as used in the specification and claims, the term heteroaryl designates a C_5 - C_{10} aromatic ring system containing 1, 2 or 3 heteroatoms, which may be the same or different, selected from N, O or S. Such heteroaryl ring systems
- 25 include pyrrolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinoliny, isoquinoliny, indoliny, benzothienyl, benzofuranyl, benzisoxazolyl or the like. The term aryl designates a carbocyclic aromatic ring system such as phenyl, naphthyl, anthracenyl or the like. The term haloalkyl as used herein designates a C_nH_{2n+1}

group having from one to $2n+1$ halogen atoms which may be the same or different and the term haloalkoxy as used herein designates an OC_nH_{2n+1} group having from one to $2n+1$ halogen atoms which may be the same or different.

In the specification and claims, when the terms C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl, cycloheteroalkyl, aryl or heteroaryl are designated as being optionally substituted, the substituent groups which are optionally present may be one or more of those customarily employed in the development of pharmaceutical compounds or the modification of such compounds to influence their structure/activity, persistence, absorption, stability or other beneficial property.

Specific examples of such substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl or cycloalkyl groups, preferably halogen atoms, NO_2 or CF_3 groups. Typically, 0-3 substituents may be present, preferably 1 or 2. When any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12, preferably up to 6, more preferably up to 4 carbon atoms.

Pharmaceutically acceptable salts may be any acid addition salt formed by a compound of formula I and a pharmaceutically acceptable acid such as phosphoric, sulfuric, nitric, hydrochloric, hydrobromic, citric, malic, maleic, malonic, mandelic, succinic, fumaric, tartaric, propionic, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like.

Compounds of the invention include esters, carbamates or other conventional prodrug forms, which in general, are functional derivatives of the compounds of the invention and which are readily converted to the inventive active moiety *in vivo*. Correspondingly, the method of the invention embraces the treatment of the various conditions described hereinabove with a compound of formula I or with a compound which is not specifically disclosed but which, upon administration, converts to a compound of formula I *in vivo*. Also included are metabolites of the compounds of the present invention defined as active species produced upon introduction of these compounds into a biological system.

Compounds of the invention may exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich or selectively prepare said stereoisomers. Accordingly, the present invention comprises compounds of Formula I, the stereoisomers thereof and the pharmaceutically acceptable salts thereof. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active or enantiomerically pure form.

Preferred compounds of the invention are those compounds of the invention are those compounds of formula I wherein R_2 is an optionally substituted phenyl or heteroaryl group. Also preferred are those compounds of formula I wherein R_1 is H. Another group of preferred compounds of formula I are those compounds wherein R_3 is a C_5 - C_7 cycloheteroalkyl, heteroaryl or phenyl group each optionally substituted with one or two halogen, CN, NO_2 , CF_3 , methoxy, carboxy or SOR_{26} groups.

More preferred compounds of the invention are those compounds of formula I wherein R_2 is an optionally substituted phenyl or heteroaryl group and R_4 is H, phenyl or C_1 - C_4 alkyl optionally substituted with one hydroxy or phenyl group. Another group of more preferred compounds are those compounds of formula I wherein R_2 is an optionally substituted phenyl or heteroaryl group and R_3 is a thienyl, pyridyl or phenyl group each optionally substituted with one or two halogen, CN, NO_2 , CF_3 , methoxy, carboxy or $SOCH_3$ groups. Further more preferred compounds of formula I are those compounds wherein R_1 is H; R_2 is a phenyl group substituted with one or two halogen; and R_3 is a phenyl group substituted with one NO_2 or CF_3 group.

Examples of the preferred compounds of formula I include:

2-(3-fluorophenyl)-4-(3-nitrophenyl)-1,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-3(2H)-one;

2-(3-fluorophenyl)-6-methyl-4-(3-nitrophenyl)-1,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-3(2H)-one;

2-(4-chlorophenyl)-6-methyl-4-[3-(trifluoromethyl)phenyl]-1,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-3(2H)-one;


2-(4-chlorophenyl)-6-methyl-4-(3-fluorophenyl)-1,6-dihydrodipyrzolo-

[3,4-b:3'4'-d]pyridin-3(2H)-one;
 4-(5-bromo-3-pyridinyl)-6-methyl-3-[(trifluoromethyl)phenyl]-1,6-dihydrodipyrzolo-
 [3,4-b:3',4'-d]pyridin-3(2H)-one;
 4-(5-bromo-3-pyridinyl)-3-(4-fluorophenyl)-6-methyl-1,6-dihydrodipyrzolo-
 5 [3,4-b:3',4'-d]pyridin-3(2H)-one;
 methyl 3-{6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo-
 [3,4-b:3',4'-d]pyridin-2(1H)-yl}benzoate;
 2-chloro-5-{6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo-
 [3,4-b:3',4'-d]pyridin-2(1H)-yl}benzoic acid;
 10 4-(3-bromophenyl)-6-methyl-2-(4-nitrophenyl)-1,6-dihydrodipyrzolo[3,4-b:3',4'-d]-
 pyridin-3(2H)-one;
 4-[4-(3-bromophenyl)-6-methyl-3-oxo-3,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-2(1H)-
 yl]-2-chlorobenzoic acid;
 methyl 2-fluoro-4-{6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydrodipyrzolo-
 15 [3,4-b:3',4'-d]pyridin-2(1H)-yl}benzoate;
 the stereoisomers thereof; or the pharmaceutically acceptable salts thereof.

Compounds of formula I may be prepared using conventional synthetic methods and, if required, standard separation or isolation techniques.

For example, for compounds of formula I wherein R₁ is H (Ia), an aryl,
 20 heteroaryl or heterocycloalkyl ester of formula II may undergo a Knoevenagel
 condensation to give the oxo ester of formula III; said oxo ester is allowed to react
 with an aminopyrazole of formula IV in the presence of a base to give the
 hydroxypyrazolopyridine of formula V; said hydroxypyrazolopyridine is then
 converted to the corresponding chloro compound of formula VI via reaction with a
 25 chlorinating agent such as thionyl chloride or phosphorous oxychloride; the resultant
 chloro compound may undergo an addition-elimination reaction with a hydrazine of
 formula VII to give the hydrazinyl intermediate of formula VIII; and cyclization of the
 formula VIII compound gives the desired product of formula Ia. The reaction is
 illustrated in flow diagram I.


30

Flow Diagram I

- 5 Cyclization of the intermediates of formula VIII is accomplished in the presence of an acid such as acetic acid or a base such as sodium methoxide or sodium hydride. Alternatively, the chloro intermediate of formula VI may be reacted with hydrazine to give the unsubstituted pyrazolone of formula IX and said

pyrazolone may be selectively alkylated with an alkyl or benzyl halide to give those compounds of formula I wherein R_2 is an optionally substituted alkyl group and R_1 is H (Ib). The reaction is shown in flow diagram II, wherein X is Cl, Br or I.

5


Flow Diagram II

- Compounds of formula I wherein R_1 is H and R_3 is a nitrogen containing heteroaryl or cycloheteroaryl group and is attached through said nitrogen atom (Ic) may be prepared by reacting the aminopyrazole carboxylate of formula IV with diethyl malonate in the presence of a base to give a pyridone of formula X; treating said pyridone with a chlorinating agent to give the monochloro compound of formula XI; reacting said monochloro compound with the substituted hydrazine of formula VII to give a hydrazinyl intermediate and cyclizing said intermediate as described in flow diagram I hereinabove to give the di-ketone of formula XII; reacting said di-ketone with a chlorinating agent such as POCl_3 to give the di-chloro compound of formula XIII; selectively displacing one chlorine atom with a nucleophile such as an amine or

an aniline, R_3 , and hydrolyzing the second chloro group to give the desired formula Ic product. The reaction is shown in flow diagram III.

Flow Diagram III

5




Alternatively, the pyridone intermediate of formula XI may be converted to the trifluoromethylsulfonate of formula XIV via reaction with trifluoromethane sulfonyl (tfs) chloride or tfs anhydride in the presence of a base such as an organic base, i.e. pyridine, triethyl amine or lutidine. The thus-obtained formula XIV compound may

10

undergo an aryl-aryl cross coupling with an aryl boronate or aryl stannate of formula XV in the presence of a catalyst to yield the chloro intermediate of formula VI and said intermediate may then be carried on to those compounds of formula I wherein R_1 is H and R_3 is aryl (Id) as described hereinabove in flow diagram I. The reaction is shown in flow diagram IV wherein M represents B or Sn.

Flow Diagram IV



10

Advantageously, the compounds of formula I are useful for the treatment of immune disorders related to or affected by the immune regulatory protein B7-1 such as transplant rejection, graft vs host disease or an autoimmune disease such as multiple sclerosis, rheumatoid arthritis, diabetes mellitus, Grave's disease, pernicious anemia, myasthenia gravis, rheumatic fever, systemic lupus erythematosus, vitiligo, autoimmune Addison's disease, Hashimoto's thyroiditis, Crohn's disease or the like. Accordingly, the present invention provides a method for the treatment of an immune disorder related to or affected by the immune regulatory protein B7-1 which

15

comprises providing a patient in need thereof with an immunotherapeutically effective amount of a compound of formula I as described hereinabove. The compounds may be provided by oral or parenteral administration or in any common manner known to be an effective administration of an immunotherapeutic agent to a patient in need thereof.

The term "providing" as used herein with respect to providing a compound or substance embraced by the invention, designates either directly administering such a compound or substance, or administering a prodrug, derivative or analogue which forms an equivalent amount of the compound or substance within the body.

The immunotherapeutically effective amount provided in the treatment of a specific immune disorder may vary according to the specific condition(s) being treated, the size, age and response pattern of the patient, the severity of the disorder, the judgment of the attending physician and the like. In general, effective amounts for daily oral administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg.

In actual practice, the compounds of the invention are provided by administering the compound or a precursor thereof in a solid or liquid form, either neat or in combination with one or more conventional pharmaceutical carriers or excipients. Accordingly, the present invention provides a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula i as described hereinabove.

Solid carriers suitable for use in the composition of the invention include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating agents or encapsulating materials. In powders, the carrier may be a finely divided solid which is in admixture with a finely divided compound of formula i. In tablets, the formula i compound may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Said powders and tablets may contain up to 99% by weight of the formula i compound. Solid carriers suitable for use in the composition of the invention include calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin,

cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Any pharmaceutically acceptable liquid carrier suitable for preparing solutions, suspensions, emulsions, syrups and elixirs may be employed in the composition of the invention. Compounds of formula I may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof. Said liquid composition may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo-regulators, or the like. Examples of liquid carriers suitable for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) or their derivatives, or oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier may also be an oily ester such as ethyl oleate or isopropyl myristate.

Compositions of the invention which are sterile solutions or suspensions are suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions may also be administered intravenously. Inventive compositions suitable for oral administration may be in either liquid or solid composition form.


For a more clear understanding, and in order to illustrate the invention more clearly, specific examples thereof are set forth hereinbelow. The following examples are merely illustrative and are not to be understood as limiting the scope and underlying principles of the invention in any way.

The term HNMR designates proton nuclear magnetic resonance. The terms EtOAc, THF and DMF designate ethyl acetate, tetrahydrofuran and dimethyl formamide, respectively. All chromatography is performed using SiO₂ as support.


30

EXAMPLE 1**Preparation of Ethyl 3-Methoxy-3-(5-bromo-3-pyridinyl)-2-propenoate**

5



- 10 A solution of methyl 5-bromonicotinate (15.0g, 69.4 mmol) in ethyl acetate is treated with NaH (60% in mineral oil, 2.4 g) and gently heated at 40°C until a mild exotherm occurs. After cessation of reflux, the reaction mixture is treated with additional NaH (2.27 g, 139 mmol total), heated at reflux temperature for 16h, cooled to room temperature and diluted with CH_2Cl_2 and water. The organic phase is
- 15 separated, washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The resultant oil is dissolved in acetonitrile and methanol, treated with a 2M solution of trimethylsilyl diazomethane (TMSCHN_2) in hexanes (70 ml, 140 mmol), stirred for 36h and treated with 5% aqueous HCl. After cessation of nitrogen evolution, the phases are separated and the organic phase is washed with brine, dried over Na_2SO_4 and
- 20 concentrated *in vacuo*. The resultant residue is chromatographed through a plug of silica gel (4:1 hexanes:EtOAc) to give the title compound as a light brown solid, 10.1 g (53% yield), identified by HNMR and mass spectral analyses.


EXAMPLE 2**Preparation of Ethyl 4-Chloro-6-(5-bromo-3-pyridinyl)-1-methyl-5-****pyrazolopyridinecarboxylate**

10 A solution of ethyl 5-amino-1-methyl-4-pyrazole carboxylate (5.91 g, 35 mmol) in THF is treated with NaH (60% in mineral oil, 4.1 g, 122 mmol), stirred for 0.5h, treated with ethyl 3-methoxy-3-(5-bromo-3-pyridinyl)-2-propenoate (10.0 g, 35 mmol), heated at reflux temperature for 36h, cooled to 0°C, acidified to pH 5 with aqueous HCl and extracted with EtOAc. The combined extracts are washed with brine, dried


15 over Na₂SO₄ and concentrated *in vacuo*. The resultant residue is triturated with hexanes to give the 4-hydroxy precursor of the title product as a white solid, 9 g, identified by HNMR. This solid is dissolved in POCl₃ (150 mL), heated at reflux temperature for 2h and concentrated *in vacuo*. The resultant residue is dissolved in EtOAc, cooled to 0°C and neutralized with aqueous NaHCO₃. The organic phase is

20 separated, washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. This residue is chromatographed on silica gel (3:1 hexanes:EtOAc) to give the title product as a white powder, 7.43 g (65% yield over 2 steps), identified by HNMR and mass spectral analyses.

25

EXAMPLE 3**Preparation of Ethyl 4-[N'-(3-Fluorophenyl)hydrazino]-1-methyl-6-(5-bromo-3-pyridinyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate**


A solution of ethyl 4-chloro-6-(5-bromo-3-pyridinyl)-1-methyl-5-pyrazolopyridinecarboxylate (1.3 g, 3.28 mmol) in ethanol is treated with 3-fluorophenylhydrazine (1.03 g, 8.2 mmol), heated at reflux temperature for 6h and concentrated *in vacuo*. The resultant residue is chromatographed (silica gel, 1:1 hexanes:EtOAc) to afford the title product as a white foam, 1.1 g (69% yield), identified by HNMR and mass spectral analyses.

EXAMPLE 4**Preparation of 4-(5-Bromo-3-pyridinyl)-2-(3-fluorophenyl)-6-methyl-1,6-dihydrodipyrzalo[3,4-b:3,4-d]pyridin-3(2H)-one**

A solution of ethyl 4-[N'-(3-fluorophenyl)hydrazino]-1-methyl-6-(5-bromo-3-pyridinyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (1.0g, 2.11 mmol) in DMF is treated with NaH (0.15 g, 8.75 mmol) heated at 90°C for 12h, poured into ice water, acidified to pH3 with aqueous HCl and filtered. The filtercake is washed with cold EtOAc and air-dried to afford the title product as an off-white solid, 0.8 g, (93% yield), identified by HNMR and mass spectral analyses.

EXAMPLE 5


Preparation of 4-(3-Fluorophenyl)-2-(4-chlorophenyl)-6-methyl-1,6-dihydrodipyrazolo[3,4-b:3,4-d']pyridin-3(2H)-one




A mixture of ethyl 4-[N'-(4-chlorophenyl)hydrazino]1-methyl-6-(3-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine carboxylate (0.15 g, 2.27 mmol) in acetic acid is heated at 90°C for 12h, poured into ice water and filtered. The filtercake is washed with cold EtOAc and air-dried to give the title product as an off-white solid (0.024 g (19% yield), identified by HNMR and mass spectral analyses.

EXAMPLES 6-68**Preparation of Dihydrodipyrzolopyridinone Compounds**


5




- Using essentially the same procedures described in Examples 1-5
 10 hereinabove and employing the appropriate 4-chloro-5-pyrazolopyridinecarboxylate
 substrate and aryl hydrazine reagent, the compounds shown in Table I are obtained
 and identified by HNMR and mass spectral analyses.

Table I


Ex No.	R2	R3	R4	[M+H]
6	4-Cl-C ₆ H ₄	C ₆ H ₅	CH ₃	375.817
7	3-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	C ₆ H ₅	489.4318
8	4-F-C ₆ H ₄	5-Bromo-3-pyridinyl	CH ₃	439.2465
9	2-pyridinyl	5-Bromo-3-pyridinyl	CH ₃	422.2439
10	2-pyridinyl	3-CH ₃ -C ₆ H ₄	CH ₃	356.3869

Table I (cont'd)


Ex No.	R2	R3	R4	[M+H]
11	3-CH ₃ -5-CF ₃ -C ₆ H ₃	3-CH ₃ -C ₆ H ₄	CH ₃	437.4242
12	3-CH ₃ -5-CF ₃ -C ₆ H ₃	3-Br-C ₆ H ₄	CH ₃	502.2934
13	2-pyridinyl	3-Br-C ₆ H ₄	CH ₃	421.2561
14	2-pyridinyl	5-methyl-3-pyridinyl	CH ₃	357.3747
15	3-CH ₃ -5-CF ₃ -C ₆ H ₃	5-methyl-3-pyridinyl	CH ₃	438.412
16	4-I-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	535.267
17	3,5-di-CH ₃ -C ₆ H ₃	3-Br-C ₆ H ₄	CH ₃	448.322
18	4-NO ₂ -C ₆ H ₄	3-Br-C ₆ H ₄	CH ₃	465.2659
19	3,5-di-CH ₃ -C ₆ H ₃	3-CH ₃ -C ₆ H ₄	CH ₃	383.4528
20	3,5-di-CH ₃ -C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	437.4242
21	3-CO ₂ H-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	453.3803
22	3-CO ₂ CH ₃ -C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	467.4071
23	6-ethoxy-3-pyridazinyl	3-CF ₃ -C ₆ H ₄	CH ₃	455.3992
24	6-oxo-1,6-dihydro-3-pyridazinyl	3-CF ₃ -C ₆ H ₄	CH ₃	427.3455

Table I (cont'd)


Ex No.	R2	R3	R4	[M+H]
25	3-CO ₂ H-4-Cl-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	487.825
26	3-CO ₂ CH ₃ -4-Cl-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	501.8519
27	3,5-di-CH ₃ -C ₆ H ₃	5-methyl-2-pyridyl	CH ₃	384.4406
28	3-CO ₂ C ₂ H ₅ -C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	481.434
29	3-Cl-4-CO ₂ CH ₃ -C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	501.8519
30	3-Cl-4-CO ₂ H-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	487.825
31	3-Cl-4-CO ₂ CH ₃ -C ₆ H ₃	3-Br-C ₆ H ₄	CH ₃	512.7497
32	3-Cl-4-CO ₂ H-C ₆ H ₃	3-Br-C ₆ H ₄	CH ₃	498.7228
33	4-CO ₂ H-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	453.3803
34	4-CO ₂ CH ₃ -C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	467.4071
35	3-CO ₂ CH ₃ -4-F-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	485.3976
36	3-CO ₂ H-4-F-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	471.3707
37	3-F-4-CO ₂ CH ₃ -C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	485.3976
38	3-F-4-CO ₂ H-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	471.3707
39	4-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	427.3609
40	4-NO ₂ -C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	454.3681
41	2-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	427.3609

Table I (cont'd)


Ex No.	R2	R3	R4	[M+H]
42	4-t-Bu-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	465.478
43	3-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	427.3609
44	2,4-di-F-C ₆ H ₃	3-CF ₃ -C ₆ H ₄	CH ₃	445.3514
45	4-CF ₃ -2-pyrimidinyl	3-CF ₃ -C ₆ H ₄	CH ₃	479.3443
46	4-F-C ₆ H ₄	3-NO ₂ -C ₆ H ₄	CH ₃	404.3603
47	4-F-C ₆ H ₄	3-NH ₂ -C ₆ H ₄	CH ₃	374.3773
48	4-NH ₂ -C ₆ H ₄	3-CF ₃ -C ₆ H ₄	CH ₃	424.3851
49	3-F-C ₆ H ₄	3-pyridyl	CH ₃	360.3505
50	3-F-C ₆ H ₄	3-NO ₂ -C ₆ H ₄	CH ₃	404.3603
51	2-CO ₂ C ₂ H ₅ -4-CH ₃ -3-thienyl	3-CF ₃ -C ₆ H ₄	CH ₃	501.489
52	2-CO ₂ H-4-CH ₃ -3-thienyl	3-CF ₃ -C ₆ H ₄	CH ₃	473.4353
53	3-F-C ₆ H ₄	3-CN-C ₆ H ₄	CH ₃	384.3725
54	3-F-C ₆ H ₄	3-CONH ₂ -C ₆ H ₄	CH ₃	402.3877
55	3-F-C ₆ H ₄	3-CH ₃ SO ₂ -C ₆ H ₄	CH ₃	437.4543
56	3-F-C ₆ H ₄	3-CH ₃ SO-C ₆ H ₄	CH ₃	421.4529
57	4-biphenyl	3-CF ₃ -C ₆ H ₄	CH ₃	485.4682

Table I (cont'd)

Ex No.	R2	R3	R4	[M+H]
58	4-benzyloxyphenyl	3-CF ₃ -C ₆ H ₄	CH ₃	515.4945
59	3-benzyloxyphenyl	3-CF ₃ -C ₆ H ₄	CH ₃	515.4945
60	3-F-C ₆ H ₄	3-CO ₂ H-C ₆ H ₄	CH ₃	403.3725
61	H	3-CF ₃ -C ₆ H ₄	CH ₃	410.36
62	benzyl	3-CF ₃ -C ₆ H ₄	CH ₃	423.3973
63	4-CO ₂ CH ₃ -C ₆ H ₄ -CH ₂	3-CF ₃ -C ₆ H ₄	CH ₃	481.434
64	4-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	benzyl	503.4587
65	4-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	H	414.09
66	4-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	HOCH ₂ CH ₂	458.12
67	4-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	C ₂ H ₅	441.3878
68	4-F-C ₆ H ₄	3-CF ₃ -C ₆ H ₄	n-C ₃ H ₇	455.4147

EXAMPLE 69**Preparation of Ethyl 4-Hydroxy-1-methyl-6-oxo-6,7-dihydro-1H-pyrazolo-[3,4-b]pyridine-5-carboxylate**

- 10 A solution of sodium metal (12.7 g, 0.55 mol) in ethanol is treated at room temperature with ethyl 5-amino-1-methyl-4-pyrazolecarboxylate (25 g, 0.148 mol), stirred for 0.5h, treated dropwise with a solution of diethyl malonate (80 mL, 0.52 mol) in ethanol over a 0.5h period, heated at reflux temperature for 56h, cooled to room temperature, diluted with water, washed with ethyl acetate, acidified to pH 2 with HCl
- 15 and filtered. The filtercake is washed sequentially with water, ethanol, ethyl acetate and toluene and dried *in vacuo* at 40°C for 16h to afford the title product as a white solid, 28.7 g (82% yield), identified by HNMR analysis.

EXAMPLE 70**Preparation of Ethyl 4-chloro-1-methyl-6-oxo-6,7-dihydro-1H-pyrazolo-[3,4-b]pyridine-5-carboxylate**

- 25 A solution of ethyl 4-hydroxy-1-methyl-6-oxo-6,7-dihydro-1H-pyrazolo-[3,4-b]pyridine-5-carboxylate (10 g, 42.2 mmol) in acetonitrile is treated with benzyl triethyl ammonium chloride (40.4 g, 169 mmol), followed by phosphorous oxychloride (17.6 mL, 190 mmol), heated at 40°C for 0.5h, then at reflux temperature for 2.5h,


cooled to room temperature, diluted with water (caution exotherm), stirred at ambient temperatures for 16h and filtered. The filtercake is washed with cyclohexane and dried *in vacuo* to give the title compound as a white solid, 7.87 g (73% yield), identified by HNMR analysis.

5

EXAMPLE 71

Preparation of Ethyl 4-Chloro-1-methyl-6-trifluoromethanesulfonyloxy-1H-pyrazolo[3,4-b]pyridine-5-carboxylate


10




A solution of ethyl 4-chloro-1-methyl-6-oxo-6,7-dihydro-1H-pyrazolo-[3,4-b]pyridine-5-carboxylate (2.56 g, 10 mmol) in methylene chloride and 2,6-di-
 15 butyl-4-methylpyridine (3.07 g, 15 mmol) is cooled to -78°C , treated dropwise with a solution of trifluoromethane sulfonic anhydride (3.30 mL, 18 mmol) in CH_2Cl_2 , stirred at 0°C for 4h and diluted with EtOAc. The reaction mixture is washed sequentially with saturated NaHCO_3 , water, 10% aqueous HCl, water and brine, dried over Na_2SO_4 and concentrated *in vacuo* to give the title product as a tan oil, 3.56 g (92%
 20 yield), identified by HNMR.

EXAMPLE 72**Preparation of Ethyl 4-Chloro-6-(3,5-dichlorophenyl)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate**

5



- A solution of ethyl 4-chloro-1-methyl-6-trifluoromethanesulfonyloxy-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (387 mg, 1 mmol) in THF is treated with tetrakis(triphenyl phosphine) palladium (115 mg, 10 mol%), stirred for 20 min at room temperature, treated sequentially with 3,5-dichlorobenzeneboronic acid (285 mg, 1.5 mmol), 2N K₂CO₃ (0.7 mL) and benzyl triethyl ammonium chloride (319 mg, 1.4 mmol), heated at reflux temperature for 4h, cooled to room temperature and diluted with EtOAc. The phases are separated and the organic phase is washed sequentially with water and brine, dried over Na₂SO₄ and concentrated *in vacuo*.
- 15 The resultant residue is chromatographed (silica gel, hexanes:EtOAc, 5:1) to afford the title product as a white solid, 127 mg (33% yield), identified by HNMR analysis.

EXAMPLE 73**Preparation of 4-(3,5-Dichlorophenyl)-2-(3-fluorophenyl)-6-methyl-1,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridin-3(2H)-one**

5


A solution of ethyl 4-chloro-6-(3,5-dichlorophenyl)-1-methyl-1H-pyrazolo-[3,4-b]pyridine-5-carboxylate (120 mg, 0.31 mmol) in DMF is treated with 3-fluorophenyl hydrazine (99 mg, 0.78 mmol), heated at 100°C for 10h, cooled to room temperature, diluted with water and EtOAc and filtered. The filtercake is air-dried to afford the 4-hydrazinyl intermediate as an off-white solid, 80 mg. This solid (65 mg, 0.13 mmol) is suspended in DMF, treated with NaH (14 mg, 0.41 mmol), stirred at 100°C for 3h, cooled to room temperature, diluted with EtOAc and filtered. The filtercake is air-dried to afford the title product as a pink solid, 44 mg (33% yield), identified by HNMR and mass spectral analyses.

10


15

EXAMPLES 74-77**Preparation of Dihydrodipyrzolo[3,4-b:3',4'-d]pyridinone Compounds**

20




Using essentially the same procedures described in Examples 73-76 hereinabove and employing the appropriate arylboronic acid and aryl hydrazine as reagents, the compounds shown in Table II are obtained and identified by HNMR and mass spectral analyses.

Table II

Ex No.	R2	R3	[M+H]
74	3-F-C ₆ H ₄	3-thienyl	366.0826
75	3-F-C ₆ H ₄	3-CH ₃ O-C ₆ H ₄	390.13
76	3-F-C ₆ H ₄	1,3-benzodioxol-5-yl	404.11
77	3-F-C ₆ H ₄	2-fluoro-1,1'-biphen-4-yl	454.1481

10


EXAMPLE 78**Preparation of 2-(3-Fluorophenyl)-6-methyl-1,2,5,6-tetrahydro-1,2,5,6,7-pentaza-as-indacene-3,4-dione**

A suspension of ethyl 4-chloro-1-methyl-6-(trifluoromethanesulfonyloxy)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate (524 mg, 2.05 mmol) in toluene is treated with 3-fluorophenyl hydrazine (651 mg, 5.13 mmol) and a catalytic amount of 2,6-di-
 10 butyl-4-methylpyridine, heated at reflux temperature for 36h, cooled to room temperature and filtered. The filtercake is washed with cold toluene and dried *in vacuo* to give the 4-hydrazinyl intermediate as a white powder, 624 mg (88% yield). This white powder (550 mg, 1.59 mmol) is suspended in THF, treated with NaH (60% in oil, 187 mg, 5.58 mmol), heated at reflux temperature for 24h, cooled to room
 15 temperature, quenched carefully with 10% HCl, diluted with EtOAc and filtered. The filtercake is washed sequentially with water and EtOAc and air-dried to afford the title product as a white powder, 391 mg (83% yield, 73% yield over 2 steps), identified by HNMR and mass spectral analyses.

20

EXAMPLE 79**Preparation of 3-Chloro-4-chloro-2-(3-fluorophenyl)-6-methyl-2,6-dihydropyrazolo[3,4-b:3',4'-d] pyridine**

5




10 A mixture of 2-(3-fluorophenyl)-6-methyl-1,2,5,6-tetrahydro-1,2,5,6,7-pentaza-as-indacene-3,4-dione (1.5 g, 5.02 mmol) and phosphorousoxychloride (20 mL) is heated at reflux temperature for 5h, cooled to room temperature and concentrated *in vacuo*. The resultant residue is diluted with ice water, neutralized with Na₂CO₃ and extracted with EtOAc. The extracts are combined, dried over Na₂SO₄ and concentrated *in vacuo* to afford the title product as a light yellow solid, 1.2 g (75% yield), identified by HNMR and mass spectral analyses.

15

EXAMPLE 80**Preparation of 3-Chloro-4-(2-6-dimethyl-4-morpholinyl)-2-(3-fluorophenyl)-6-methyl-2,6-dihydropyrazolo[3,4-b:3',4'-d]pyridine**


5



A mixture of 3-chloro-4-chloro-2-(3-fluorophenyl)-6-methyl-2,6-dihydropyrazolo[3,4-b:3',4'-d]pyridine (100 mg, 0.315 mmol) and 2,6-dimethylmorpholine (0.097 mL, 0.787 mmol) in DMF is heated at 140°C for 4h, cooled to room temperature, quenched with water, acidified to pH 3 with 3NHCl and extracted with EtOAc. The extracts are combined, dried over Na₂SO₄ and concentrated *in vacuo*. The resultant residue is purified by flash chromatography (silica gel, 0.5% methanol in chloroform) to afford the title product as a yellow solid, 90 mg (69% yield), mp 194.5-197°C, identified by HNMR and mass spectral analyses.

EXAMPLE 81**Preparation of 4-(2,6-Dimethyl-4-morpholinyl)-2-(3-fluorophenyl)-6-methyl-1,6-dihydrodipyrzolo[3,4-b:3'-4'-d]pyridin-3(2H)-one**

5



A solution of 3-chloro-4-(2,6-dimethyl-4-morpholinyl)-2-(3-fluorophenyl)-6-methyl-2,6-dihydrodipyrzolo[3,4-b:3',4'-d]pyridine (48 mg, 0.116 mmol) in 3:1 methanol:THF is treated with 0.4 mL of 4N NaOH₂, heated at reflux temperature for 16h, cooled to room temperature, quenched with 3N HCl and extracted with EtOAc. The extracts are combined, dried over Na₂SO₄ and concentrated *in vacuo* to afford the title product as a beige powder, 40 mg (87% yield), mp 204.7-207°C, identified by HNMR and mass spectral analyses.

15

EXAMPLE 82**Evaluation of B7-1/CD28 Binding Inhibition for Test Compounds****CD28/B7-1 ELISA**

Wells are coated with 300 ng CD28-Fc in carbonate buffer (pH 9.4) overnight at 4°C, blocked with 1% bovine serum albumin in tris-buffered saline (TBS) for 1h at 22°C and washed 3 times in TBS prior to assay. The detection complex is formed as follows: B7-1-Fc-biotin, prepared using NHS-LC-biotin (Pierce #21335) according to the manufacturers instructions (4.1 moles biotin/mole Fc), is added at 0.8 ug/ml to

25

- streptavidin-alkaline phosphatase (Caltag Sa1008 at 1:1000 in TBS. Gradient dilutions of test compound in dimethylsulfoxide (1% final) are added to this complex and incubated 30 min. at 22°C. Detection complex (+/- inhibitors) is then added to the CD28 coated wells for 25 min. at 22°C, washed 5 times with TBS, developed with
- 5 the colorimetric substrate pNPP (Pierce #34045) in diethanolamine/MgCl₂ buffer (pH 9.5) and read at 405 nm. The inhibition constant (IC₅₀) is calculated by subtracting background binding and comparing to uninhibited (DMSO alone) controls. The inhibition constant represents the concentration of test compound required to achieve 50% inhibition. The results are shown in Table III.

10

Table III

Example Number	B7-1/CD28 Inhibition IC₅₀ (nM)
4	20
5	3000
6	1800
7	750
8	200
9	400
10	150
11	3000
12	190
13	70
14	3000
15	3000
16	50
17	58
18	12
19	990
20	66
21	48

Table III (cont'd)

Example Number	B7-1/CD28 Inhibition IC50 (nM)
22	8
23	290
24	72
25	7
26	120
27	3000
28	170
29	41
30	16
31	9
32	9
33	190
34	31
35	98
36	70
37	12
38	210
39	50
40	100
41	400
42	900
43	20
44	1000
45	1200
46	50
47	400
48	50

Tabl III (cont'd)

Example Number	B7-1/CD28 Inhibition IC50 (nM)
49	3000
50	4
51	2100
52	1700
53	30
54	1500
55	1900
56	330
57	39
58	25
59	20
60	70
61	200
62	3000
63	3000
64	70
65	50
66	800
67	780
68	90
73	40
74	105
75	82
76	295
77	3000
81	188